MARY GILLIS: Open Payments
NPI 1285082925 · COLUMBUS, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$171 in 10 payments from 5 companies in 2025. Trend: 2023 $41 · 2024 $161 · 2025 $171
Food & beverage: $171
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $54 |
| Novo Nordisk Inc | 3 | $47 |
| Dexcom, Inc. | 2 | $36 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| Esperion Therapeutics, Inc. | 1 | $15 |
Products named: FARXIGA, Ozempic, Dexcom G6 Transmitter, GVOKE HYPOPEN, NEXLETOL.
Industry payments across MS — which companies pay providers there.
